Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics Inc. (NASDAQ: STIM) pioneers FDA-cleared transcranial magnetic stimulation (TMS) therapies for major depressive disorder and neurohealth conditions. This dedicated news hub provides investors and healthcare professionals with essential updates about the company's noninvasive treatment innovations, financial performance, and clinical advancements.
Discover comprehensive coverage of STIM's regulatory milestones, including NeuroStar system clearances, alongside analyses of quarterly earnings and strategic collaborations. The page consolidates official press releases about TMS therapy adoption across treatment networks and developments in adolescent mental health applications.
Key updates include FDA decision alerts, partnership announcements with clinical providers like Greenbrook TMS, and presentations of new outcomes data from the world's largest depression treatment registry. Investors gain insights into operational expansions while medical professionals track evidence-based protocol enhancements.
Bookmark this page for streamlined access to Neuronetics' verified corporate communications and therapeutic innovation updates. Regularly refreshed content ensures you stay informed about advancements in non-pharmaceutical depression treatment technologies.
Neuronetics announced its participation in the 12th Annual Clinical TMS Society (CTMSS) Meeting in London from June 13-15, 2024. They will present six posters and one oral presentation showcasing data from the NeuroStar TMS System. Highlights include early prediction of nonresponse in major depressive disorder, the impact of treatment timing, efficacy of accelerated TMS protocols, effectiveness in adolescents, and symptom sensitivity to TMS treatment. NeuroStar will also exhibit at booth #303, aiming to establish itself as the leading provider of TMS devices.
Neuronetics (NASDAQ: STIM) announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 6, 2024, at 10:00am Central Time. The presentation will be accessible via a live audio webcast on their investor relations webpage. Neuronetics, a medical technology company, focuses on developing and marketing products to improve the lives of patients with neurohealth disorders.
Neuronetics (NASDAQ: STIM) announced that Humana is the first commercial payer to update its policy following the recent FDA clearance for NeuroStar TMS therapy for adolescents aged 15-21 with major depressive disorder (MDD). This policy change, effective April 25, 2024, comes just one month after the FDA's March 25, 2024 clearance. Humana's TMS coverage, previously to individuals 18 and older, now includes those aged 15-17, subject to medical director review. Humana covers around 600,000 commercial lives in the U.S. This significant advancement highlights the urgent mental health needs of the adolescent population and reinforces Neuronetics' strategic focus on advocating for health policy updates.
Neuronetics reported record first-quarter 2024 financial and operating results with revenue of $17.4 million, a 12% increase year-over-year. The U.S. treatment session revenue increased by 22%, and NeuroStar Advanced Therapy system revenue was $3.3 million. The company achieved a major milestone with FDA clearance for NeuroStar as a first-line adjunct treatment for adolescent major depressive disorder. Operating expenses decreased, resulting in a net loss of $(7.9) million for the quarter.
Neuronetics, Inc. granted inducement awards of Restricted Stock Units to thirteen new non-executive employees totaling 55,650 shares of common stock. The awards were approved under NASDAQ Listing Rule 5635(c)(4) as incentives for their employment. The RSU grants vest over four years subject to continued service, following the terms of the Neuronetics 2020 Inducement Plan.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
